Literature DB >> 25877893

Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.

Michaela Semeraro1, Sylvie Rusakiewicz2, Véronique Minard-Colin3, Nicolas F Delahaye4, David Enot5, Frédéric Vély6, Aurélien Marabelle7, Benjamin Papoular4, Christelle Piperoglou8, Mirco Ponzoni9, Patrizia Perri9, Andrei Tchirkov10, Jessica Matta11, Valérie Lapierre12, Tala Shekarian7, Sandrine Valsesia-Wittmann7, Frédéric Commo4, Nicole Prada4, Vichnou Poirier-Colame4, Brigitte Bressac13, Sophie Cotteret4, Laurence Brugieres14, Françoise Farace15, Nathalie Chaput2, Guido Kroemer16, Dominique Valteau-Couanet3, Laurence Zitvogel17.   

Abstract

The immunosurveillance mechanisms governing high-risk neuroblastoma (HR-NB), a major pediatric malignancy, have been elusive. We identify a potential role for natural killer (NK) cells, in particular the interaction between the NK receptor NKp30 and its ligand, B7-H6, in the metastatic progression and survival of HR-NB after myeloablative multimodal chemotherapy and stem cell transplantation. NB cells expressing the NKp30 ligand B7-H6 stimulated NK cells in an NKp30-dependent manner. Serum concentration of soluble B7-H6 correlated with the down-regulation of NKp30, bone marrow metastases, and chemoresistance, and soluble B7-H6 contained in the serum of HR-NB patients inhibited NK cell functions in vitro. The expression of distinct NKp30 isoforms affecting the polarization of NK cell functions correlated with 10-year event-free survival in three independent cohorts of HR-NB in remission from metastases after induction chemotherapy (n = 196, P < 0.001), adding prognostic value to known risk factors such as N-Myc amplification and age >18 months. We conclude that the interaction between NKp30 and B7-H6 may contribute to the fate of NB patients and that both the expression of NKp30 isoforms on circulating NK cells and the concentration of soluble B7-H6 in the serum may be clinically useful as biomarkers for risk stratification.
Copyright © 2015, American Association for the Advancement of Science.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25877893     DOI: 10.1126/scitranslmed.aaa2327

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  62 in total

1.  NKp30 and its ligands: emerging players in tumor immune evasion from natural killer cells.

Authors:  Elke Pogge von Strandmann; Olga Shatnyeva; Hinrich P Hansen
Journal:  Ann Transl Med       Date:  2015-11

Review 2.  The B7 Family Member B7-H6: a New Bane of Tumor.

Authors:  Ying Chen; Jun Mo; Xi Jia; Yang He
Journal:  Pathol Oncol Res       Date:  2017-10-31       Impact factor: 3.201

3.  Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.

Authors:  Laetitia Fend; Sylvie Rusakiewicz; Julien Adam; Bérangère Bastien; Anne Caignard; Meriem Messaoudene; Christina Iribarren; Isabelle Cremer; Aurélien Marabelle; Christophe Borg; Michaela Semeraro; Luc Barraud; Jean-Marc Limacher; Alexander Eggermont; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-05-13       Impact factor: 8.110

4.  NKp30 isoforms and NKp46 transcripts in metastatic melanoma patients: Unique NKp30 pattern in rare melanoma patients with favorable evolution.

Authors:  Meriem Messaoudene; Giulia Fregni; David Enot; Nicolas Jacquelot; Emmanuelle Neves; Nathalie Germaud; Henri Jean Garchon; Wahid Boukouaci; Ryad Tamouza; Johan Chanal; Marie-Françoise Avril; Antoine Toubert; Laurence Zitvogel; Sylvie Rusakiewicz; Anne Caignard
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

5.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

6.  B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.

Authors:  Yi Zhou; Yun Xu; Lujun Chen; Bin Xu; Changping Wu; Jingting Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

7.  Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma.

Authors:  Fabio Morandi; Loredana Amoroso; Alessandra Dondero; Roberta Castriconi; Stefano Parodi; Roberto Luksch; Fiorina Casale; Aurora Castellano; Alberto Garaventa; Alessandro Moretta; Cristina Bottino; Mirco Ponzoni; Maria Valeria Corrias
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

8.  Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer.

Authors:  Zhenyu Xu; Jing Shen; Maggie Haitian Wang; Tao Yi; Yangyang Yu; Yinxin Zhu; Bo Chen; Jianping Chen; Longfei Li; Minxing Li; Jian Zuo; Hui Jiang; Dexi Zhou; Jiajie Luan; Zhangang Xiao
Journal:  Oncoimmunology       Date:  2016-07-11       Impact factor: 8.110

9.  The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.

Authors:  Sonja Textor; Felicitas Bossler; Kai-Oliver Henrich; Moritz Gartlgruber; Julia Pollmann; Nathalie Fiegler; Annette Arnold; Frank Westermann; Nina Waldburger; Kai Breuhahn; Sven Golfier; Mathias Witzens-Harig; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-07-28       Impact factor: 8.110

Review 10.  Genetic discoveries and treatment advances in neuroblastoma.

Authors:  Rochelle Bagatell; Susan L Cohn
Journal:  Curr Opin Pediatr       Date:  2016-02       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.